Page 26 - 南京医科大学自然版

第45卷第7期
·924 · 南 京 医 科 大 学 学 报 2025年7月

environment in a 4T1 orthotopic mouse model［J］. Cancer ［115］LEWIS L，THOMPSON B，STELLMAKER R，et al. Body
Gene Ther，2022，29（5）：456-465 composition and chemotherapy toxicities in breast cancer：
［102］PONTERIO E，DE⁃MARIA R，HAAS T L. Identification a systematic review of the literature［J/OL］. J Cancer Sur⁃
of targets to redirect CAR T cells in glioblastoma and viv，2024.［2024 ⁃ 01 ⁃ 11］. DOI：10.1007/s11764 ⁃ 023 ⁃
colorectal cancer：an arduous venture［J］. Front Immunol， 01512⁃Z
2020，11：565631 ［116］NELSON A，MCMULLEN N，GEBREMESKEL S，et al.
［103］STERNER R C，STERNER R M. CAR⁃T cell therapy：cur⁃ Fusogenic vesicular stomatitis virus combined with natu⁃
rent limitations and potential strategies［J］. Blood Cancer ral killer T cell immunotherapy controls metastatic breast
J，2021，11（4）：69 cancer［J］. Breast Cancer Res，2024，26（1）：78
［104］PONTERIO E，HAAS T L，DE⁃MARIA R. Oncolytic virus ［117］GEBREMESKEL S，NELSON A，WALKER B，et al. Natu⁃
and CAR⁃T cell therapy in solid tumors［J］. Front Immu⁃ ral killer T cell immunotherapy combined with oncolytic
nol，2024，15：1455163 vesicular stomatitis virus or reovirus treatments differen⁃
［105］EVGIN L，VILE R G. Parking CAR T cells in tumours：on⁃ tially increases survival in mouse models of ovarian and
colytic viruses as valets or vandals?［J］. Cancers（Basel）， breast cancer metastasis［J］. J Immunother Cancer，2021，

2021，13（5）：1106 9（3）：e002096
［106］ZHU G D，ZHANG J W，ZHANG Q，et al. Enhancement ［118］JUNG B K，KO H Y，KANG H，et al. Relaxin⁃expressing
of CD70 ⁃ specific CAR T treatment by IFN ⁃ γ released oncolytic adenovirus induces remodeling of physical and
from oHSV⁃1⁃infected glioblastoma［J］. Cancer Immunol immunological aspects of cold tumor to potentiate PD⁃ 1
Immunother，2022，71（10）：2433-2448 blockade［J］. J Immunother Cancer，2020，8（2）：e000763
［107］TANG X Y，LI Y X，MA J Y，et al. Adenovirus⁃mediated ［119］ZHU B，YANG J R，JIANG Y Q，et al. Gene therapy of
specific tumor tagging facilitates CAR⁃T therapy against lung adenocarcinoma using herpes virus expressing a fu⁃
antigen⁃mismatched solid tumors［J］. Cancer Lett，2020， sogenic membrane glycoprotein［J］. Cell Biochem Bio⁃
487：1-9 phys，2014，69（3）：583-587
［108］SHIMIZU K，IYODA T，YAMASAKI S，et al. NK and ［120］SOLIMAN H，HOGUE D，HAN H，et al. Oncolytic T⁃VEC
NKT cell⁃mediated immune surveillance against hemato⁃ virotherapy plus neoadjuvant chemotherapy in nonmeta⁃
logical malignancies［J］. Cancers（Basel），2020，12（4）： static triple ⁃ negative breast cancer：a phase 2 trial［J］.
817 Nat Med，2023，29（2）：450-457
［109］NELSON A，LUKACS J D，JOHNSTON B. The current ［121］BAN W Y，GUAN J H，HUANG H W，et al. Emerging sys⁃
landscape of NKT cell immunotherapy and the hills temic delivery strategies of oncolytic viruses：a key step to⁃
ahead［J］. Cancers（Basel），2021，13（20）：5174 ward cancer immunotherapy［J］. Nano Res，2022，15（5）：
［110］BENLAGHA K，WEISS A，BEAVIS A，et al. In vivo iden⁃ 4137-4153
tification of glycolipid antigen⁃specific T cells using fluo⁃ ［122］VIJAYAKUMAR G，PALESE P，GOFF P H. Oncolytic
rescent CD1d tetramers［J］. J Exp Med，2000，191（11）： Newcastle disease virus expressing a checkpoint inhibitor
1895-1903 as a radioenhancing agent for murine melanoma［J］. EBio⁃
［111］SATOH M，IWABUCHI K. Contribution of NKT cells and Medicine，2019，49：96-105
CD1d⁃expressing cells in obesity⁃associated adipose tis⁃ ［123］BAHREYNI A，LIU H T，MOHAMUD Y，et al. A new
sue inflammation［J］. Front Immunol，2024，15：1365843 miRNA⁃modified coxsackievirus B3 inhibits triple nega⁃
［112］WU T N，HUNG J T，HUNG T H，et al. Effective suppres⁃ tive breast cancer growth with improved safety profile in
sion of tumor growth and hepatic metastasis of neuroblas⁃ immunocompetent mice［J］. Cancer Lett，2022，548：
toma by NKT ⁃ stimulatory phenyl glycolipid［J］. Biomed 215849
Pharmacother，2024，177：117040 ［124］CHEN L T，MA Z J，XU C，et al. Progress in oncolytic
［113］JUTHANI R，PUNATAR S，MITTRA I. New light on che⁃ viruses modified with nanomaterials for intravenous appli⁃
motherapy toxicity and its prevention［J］. BJC Rep，2024， cation［J］. Cancer Biol Med，2023，20（11）：830-855
2（1）：41 ［125］LEMOS D M A，FRANCO L S，MCFADDEN G. Oncolytic
［114］MANAVI M A，FATHIAN⁃NASAB M H，MOHAMMAD J viruses and the immune system：the dynamic Duo［J］.
R，et al. Mechanisms underlying dose⁃limiting toxicities Mol Ther Methods Clin Dev，2020，17：349-358
of conventional chemotherapeutic agents［J］. J Chemoth⁃ ［收稿日期］ 2025-01-13
er，2024，36（8）：623-653 （本文编辑：陈汐敏）